A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 (80μg Estradiol/4mg Progesterone and 160μg Estradiol/8mg Progesterone Intravaginal Rings) in Healthy PostMenopausal Women
Latest Information Update: 18 Oct 2024
At a glance
- Drugs Estradiol/progestogen (Primary) ; Estradiol; Progestogen
- Indications Genitourinary disorders; Menopausal syndrome; Vasomotor symptoms
- Focus Pharmacokinetics
- Sponsors Dare Bioscience
- 26 Jan 2023 According to a Dare Bioscience media release, data published in the journal Menopause, which is the journal of the North American Menopause Society.
- 06 Dec 2022 Status changed from active, no longer recruiting to completed.
- 01 Sep 2021 According to a Dar Bioscience media release, data will be presented at the European Menopause and Andropause Society (EMAS) 13th European Congress on Menopause and Andropause.